small molecule

DOVATO

DOLUTEGRAVIR SODIUM; LAMIVUDINE

Loss of exclusivityJanuary 2031latest FDA-listed patent expiry

CompanyViiV Healthcare →View the full company profile on CliffBio

Drug detail

Brand name	DOVATO
Active ingredient	DOLUTEGRAVIR SODIUM; LAMIVUDINE
Strength	EQ 50MG BASE;300MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	April 2019
Marketing status	RX

Listed patents

Patent	Expires	Type
11234985	January 2031	product
9242986*PED	June 2030	—
9242986	December 2029	substance, product
8129385*PED	April 2028	—
8129385	October 2027	substance, product

Regulatory exclusivity

Code	Expires
NPP	April 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from ViiV Healthcare